They found that both the human and bacterial transporter use a sodium gradient to import nucleosides
and drugs into the cells.
It can be inhibited either by nucleoside
, nucleotide analogues or by non-nucleoside analogues.
Approved March 1, 1996 for use alone or in combination with nucleoside
analogues for the treatment of HIV infection.
Analogue Reverse Transcriptase Inhibitors Generic Name Initials Trade Name Manufacturer Didanosine (1990) ddl Videx Bristol-Myers Squibb Lamivudine (1995) 3TC Epivir Glaxo Wellcome Stavudine (1994) d4T Zerit Bristol-Myers Squibb Zalcitabine (1992) ddC HIVID Hoffmann-LaRoche Zidovudine (1987) AZT/ZDV Retrovir Glaxo Wellcome Table 2.
In conjunction with the US FDA approval, the efficacy of Lumoxiti was studied in a single-arm, open-label clinical trial of 80 patients who had received prior treatment for HCL with at least two systemic therapies, including a purine nucleoside
After the DAD results appeared, the FDA announced it will study all findings on heart disease risk in people taking Ziagen and other nucleosides
. (6) In November 2008 the US government-sponsored antiretroviral treatment panel moved Ziagen plus Epivir off the "preferred" list of nucleoside
combinations to the "alternative" list.
Patients who fail to respond to standard interferon (16 weeks for HBeAg-positive or 48 weeks for HBeAg-negative disease) or pegylated interferon (48 weeks regardless of HBeAg status) may be treated with nucleoside
analogues if further treatment is indicated.
TORONTO -- A large, randomized comparison of three standard regimens for the initial treatment of HIV has demonstrated that all three are safe and effective, but a regimen of efavirenz plus two nucleosides
was significantly better at reducing HIV viral load, investigators reported at the 16th International AIDS Conference.
analogue, protease inhibitor, etc.) to a lipid backbone.
Discovered by Bristol-Myers Squibb, BARACLUDE (entecavil) is an oral nucleoside
analogue that selectivity inhibits HBV polymerase.
Reverset was also shown to be effective in patients with virus resistant to other commonly used nucleoside
analog reverse transcriptase inhibitors (NRTIs), including viruses harboring multiple thymidine analog mutations (TAMS), including the M41L and L210W mutations, and the L74V and M184V mutations.
Many people did not achieve durable virologic benefits from these drugs, mainly because they had previously taken and developed resistance to the nucleoside
analog reverse transcriptase inhibitors (NRTIs).